PACS 📈 PACS Group - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock •
PACS: Nursing Homes, Assisted Living Facilities, Senior Care Services
PACS Group, Inc. is a multifaceted healthcare company that operates a diverse portfolio of skilled nursing facilities, assisted living facilities, and independent living facilities across the United States. Through its subsidiaries, the company delivers a range of senior care services, catering to the unique needs of its residents. This includes providing medical care, rehabilitation services, and support with daily activities, all within a safe and comfortable environment. By offering a continuum of care, PACS Group, Inc. enables seniors to age in place, transitioning seamlessly between different levels of care as their needs evolve.
In addition to its operational capabilities, PACS Group, Inc. is also engaged in the acquisition, ownership, and leasing of healthcare-related properties. This strategic approach allows the company to expand its footprint, enhance its service offerings, and drive growth through strategic investments. With a focus on delivering high-quality care and exceptional patient experiences, PACS Group, Inc. has established itself as a reputable player in the healthcare industry. Founded in 2013 and headquartered in Farmington, Utah, the company has built a strong foundation for long-term success, with its common stock listed on the New York Stock Exchange (NYSE) under the ticker symbol PACS.
As a specialized healthcare company, PACS Group, Inc. operates within the Health Care Facilities sub-industry, as classified by the Global Industry Classification Standard (GICS). This sub-industry encompasses a range of companies that provide medical and healthcare services, including hospitals, nursing homes, and assisted living facilities. By focusing on the senior care segment, PACS Group, Inc. is well-positioned to capitalize on the growing demand for age-related healthcare services, driven by the aging population and increasing life expectancy. For more information about the company, its services, and its investment opportunities, visitors can access the PACS Group, Inc. website at https://pacs.com.
Additional Sources for PACS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PACS Stock Overview
Market Cap in USD | 6,319m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 2024-04-11 |
PACS Stock Ratings
Growth 5y | -53.9% |
Fundamental | 42.0% |
Dividend | - |
Rel. Strength Industry | -3037 |
Analysts | 4.67/5 |
Fair Price Momentum | 11.95 USD |
Fair Price DCF | 18.15 USD |
PACS Dividends
No Dividends PaidPACS Growth Ratios
Growth Correlation 3m | -81.9% |
Growth Correlation 12m | 5.6% |
Growth Correlation 5y | 5.6% |
CAGR 5y | -43.43% |
CAGR/Mean DD 5y | -3.22 |
Sharpe Ratio 12m | -0.61 |
Alpha | -46.30 |
Beta | -0.08 |
Volatility | 103.07% |
Current Volume | 1202.6k |
Average Volume 20d | 1111k |
As of December 21, 2024, the stock is trading at USD 13.01 with a total of 1,202,600 shares traded.
Over the past week, the price has changed by -15.57%, over one month by -24.58%, over three months by -68.09% and over the past year by -43.43%.
Partly, yes. Based on ValueRay Fundamental Analyses, PACS Group (NYSE:PACS) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 42.02 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PACS as of December 2024 is 11.95. This means that PACS is currently overvalued and has a potential downside of -8.15%.
PACS Group has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy PACS.
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PACS PACS Group will be worth about 12.9 in December 2025. The stock is currently trading at 13.01. This means that the stock has a potential downside of -0.77%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 41 | 215.1% |
Analysts Target Price | 41 | 215.1% |
ValueRay Target Price | 12.9 | -0.8% |